• About us
• Contact

Advertisement

Organisation › Details

Asklepios BioPharmaceutical Inc. (AskBio)

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease, Huntington’s disease, multiple system atrophy and congestive heart failure. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, Scotland, the company has generated hundreds of proprietary capsids and promoters, several of which have entered clinical testing. An early innovator in the gene therapy field, with over 800 employees in five countries, the company holds more than 750 patents in areas such as AAV production and chimeric and self-complementary capsids. *

 

	Start	2003-01-01 start
	Group	Bayer (Group)
	Industry	adeno-associated viral vector (AAV vector)
	Industry 2	genomic technology
	Person	Pesquin, Gustavo (Bayer 202303– CEO of AskBio before Amneal Pharma + Sanofi + Abbott + Pfizer + P&G+ BCG)
	Person 2	Mikhail, Sheila A. (AskBio 202303– Board Director + Adviser before CEO + Co-Founder)
	Region	Research Triangle Park, NC
	Country	United States (USA)
	Street	20 T.W. Alexander Drive Suite 110
	City	27709 Research Triangle Park, NC
	Tel	+1-919-933-4990
		Address record changed: 2024-01-05
Basic data	Employees	E: 501 to 1,000 (2023-03-09)
		* Document for »About Section«: Bayer AG. (3/9/23). "Press Release: AskBio Announces Gustavo Pesquin as New CEO". Research Triangle Park, NC.
		Record changed: 2024-06-07

Advertisement

More documents for Bayer (Group)

• [1] Roivant Sciences GmbH. (9/10/24). "Press Release: Roivant Unveils New Pipeline Program Mosliciguat, a Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator". Basel, London & New York, NY....
• [2] NextRNA Therapeutics, Inc.. (8/28/24). "Press Release: Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-coding RNAs (lncRNAs) in Oncology". Berlin & Boston, MA....
• [3] Bayer AG. (7/17/24). "Press Release: Darolutamide Meets Primary Endpoint in Phase III ARANOTE Trial in Men with Metastatic Hormone-sensitive Prostate Cancer [Not intended for U.S. and UK Media]". Berlin....
• [4] BlueRock Therapeutics LP. (5/30/23). "Press Release: BlueRock Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Parkinson’s Disease Cell Therapy Candidate Bemdaneprocel". Berlin & Cambridge, MA....
• [5] H. Lundbeck A/S. (5/13/24). "Press Release: Maria Alfaiate Appointed New Executive Vice President Commercial and Corporate Strategy at Lundbeck"....
• [6] WhiteLab Genomics. (5/6/24). "Press Release: WhiteLab Genomics Establishes US Presence by Securing Spot at Bayer Co.Lab and Ginkgo Bioworks’ Technology Network". Cambridge, MA....
• [7] Evotec SE. (4/30/24). "Press Release: Bayer and Evotec Collaborate to Advance Precision Cardiology". Berlin & Hamburg....
• [8] ProBioGen AG. (4/30/24). "Press Release: Change in Management". Berlin....
• [9] Aignostics GmbH. (3/14/24). "Press Release: Bayer and Aignostics to Collaborate on Next Generation Precision Oncology"....
• [10] CRISPR Therapeutics AG. (3/13/24). "Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors". Zug & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.